Compare Travere Therapeutics Inc. Common Stock (TVTX) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs TeraWulf Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while TeraWulf Inc trades at $11.34 (market cap $6.59B). The key difference: TeraWulf Inc is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and TeraWulf Inc for 18 Days on average.
| TVTX | WULF | |
|---|---|---|
Market Cap | $4.88B | $6.59B |
Volume | 1,668,577 | 33,904,053 |
Sector | Health | Financials |
52-Week High | $67.52 | $28.98 |
52-Week Low | $26.79 | $10.99 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $5.01B | $9.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
WULF trades at $13.21, down 1.2% on the day, with a bearish technical signal from moving averages. The company reported a net loss of -$661.42M in 2025, with a negative net income margin of -1,179.94%, though it maintains a high gross profit margin of 69.26%. Recent news highlights its pivot to AI data centers, with shares experiencing volatility amid sector-wide momentum.
Analyst consensus is strongly bullish with a $34.92 price target, but high valuation ratios and persistent losses pose significant risks. Investment appeal hinges on successful execution of the AI infrastructure strategy amid substantial financial leverage and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
